Stephen Garland is the CEO and Founder of NQuiX Ltd, a company specialising in small-molecule lead generation for drug discovery. He is a highly accomplished pre-clinical project manager and program leader, with broad-ranging understanding of the drug discovery process and personal expertise in computational chemistry and cheminformatics. He has a strong track record working across various therapeutic areas including neuroscience, oncology, metabolic, respiratory, cardiovascular and infectious diseases, as well as significant experience in most target classes, with a particular emphasis on G-Protein Coupled Receptors (GPCRs) and Protein-Protein Interactions (PPIs). He has contributed to the discovery of more than a dozen compounds in clinical development, as well as the marketed antibiotic retapamulin. His research interests include less tractable targets, allosterism, peptide mimicry, chemogenomics and ultra high-throughput virtual screening. At NQuiX, he is driving the development of new business models with a particular focus on open innovation to accelerate drug discovery with academic, not-for-profit, biotech and big pharma partners globally.
Stephen has bachelor and master degrees in chemistry from Oxford University and a Ph.D. in drug design from the University of Cambridge. He was a Rhône-Poulenc Rorer Research Fellow in the department of Pharmacology at Cambridge before joining SmithKline Beecham in 1998. At SB/GSK he was variously: group leader in computational chemistry and cheminformatics; head of the 7TM Systems Modelling Group; head of Lead Generation for Neurosciences; and responsible for Compound Collection Enhancement and Portfolio Focused Chemistry. He also led a number of highly successful early-stage research programs, including notoriously difficult Family B and C GPCR targets. He left GSK to found NQuiX in 2011.